



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Identification of novel dendritic cell subset markers in human blood



Fabian Schütz, Holger Hackstein*

Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Germany

ARTICLE INFO

Article history:

Received 19 November 2013

Available online 7 December 2013

Keywords:

Dendritic cells

Human

Blood

ABSTRACT

Human dendritic cells (DC) are key regulators of innate and adaptive immunity that can be divided in at least three major subpopulations: plasmacytoid DC (pDC), myeloid type 1 DC (mDC1) and myeloid type 2 DC (mDC2) exhibiting different functions. However, research, diagnostic and cell therapeutic studies on human DC subsets are limited because only few DC subset markers have been identified so far. Especially mDC2 representing the rarest blood DC subset are difficult to be separated from mDC1 and pDC due to a paucity of mDC2 markers. We have combined multiparameter flow cytometry analysis of human blood DC subsets with systematic expression analysis of 332 surface antigens in magnetic bead-enriched blood DC samples. The initial analysis revealed eight novel putative DC subset markers CD26, CD85a, CD109, CD172a, CD200, CD200R, CD275 and CD301 that were subsequently tested in bulk peripheral blood mononuclear cell (PBMC) samples from healthy blood donors. Secondary analysis of PBMC samples confirmed three novel DC subset markers CD26 (dipeptidyl peptidase IV), CD85a (Leukocyte immunoglobulin-like receptor B3) and CD275 (inducible costimulator ligand). CD85a is specifically expressed in mDC1 and CD26 and CD275 represent novel mDC2 markers. These markers will facilitate human DC subset discrimination and additionally provide insight into potentially novel DC subset-specific functions.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Dendritic cells (DCs) are a heterogeneous group of professional antigen presenting cells playing essential roles in the induction and regulation of immune responses to allo- and autoantigens in infectious diseases, cancer, autoimmunity, transplantation and vaccination [1–4]. Human blood DC are of special interest for both research and clinical application because they are easily accessible. However, human blood DC can be separated in functionally distinct subsets, exhibiting a complex phenotype and are present in peripheral blood of healthy individuals at very low frequencies ranging from 0.0% to 0.59% of all leukocytes [5]. Based on a consensus report, human blood DCs are divided in three major subsets that are plasmacytoid DCs (pDC) and 2 types of myeloid DCs (mDC1 and mDC2) according to the expression of CD303, CD1c and CD141, respectively [6]. Importantly, for proper DC subset discrimination additional staining of lineage marker, at least CD19+ and CD14+ has been recommended to exclude B cells and monocytes co-expressing CD1c and CD141 [6,7].

Accurate separation of blood DC subsets is critical because an increasing number of publications have reported unique functional features not only for pDC and mDC but additionally for mDC1 and mDC2 subsets. mDC1 have been reported to phagocytose *Escherichia coli* and to suppress T cell proliferation in an IL-10 dependent manner in contrast to mDC2 [8]. mDC2 have been revealed to represent a unique myeloid DC subset cross-presenting antigens to CD8 α + cytotoxic T cells indicating that mDC2 may be particularly effective in DC vaccination trials [9–12]. However, mDC2 represent the rarest DC subset in peripheral blood with mean absolute numbers of only one mDC2/ μ l whole blood in healthy individuals [5,13]. In contrast, mDC1 and pDC have been reported to be >10–15-fold more frequent in healthy blood donors [5,13]. With request to mDC2, only very few DC subset markers have been described so far [7].

Here we have systematically analyzed surface markers that are broadly available to the research community for their capacity to serve as human blood DC subset markers. We have performed a stepwise approach, where we first identified novel candidate markers in DC-enriched blood samples and subsequently tested the discriminatory capacity and usability of these markers in bulk peripheral blood mononuclear leukocyte (PBMC) samples of healthy blood donors. We have identified three novel human DC subset markers that will facilitate discrimination of mDC1 (CD85a) and the rare mDC2 subset (CD26, CD275).

* Corresponding author. Address: Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Member of the German Center for Lung Research, Langhansstr. 7, D-35390 Giessen, Germany. Fax: +49 641 985 41509.

E-mail address: Holger.Hackstein@immunologie.med.uni-giessen.de (H. Hackstein).

2. Materials and methods

2.1. Cell separation and enrichment of blood DC

Human PBMC were isolated from buffy coats of healthy blood donors after informed consent by Ficoll-Paque (Pharmacia, Germany) density gradient centrifugation. The *in vitro* studies of human blood samples were approved by the ethic study board of the University Hospital Gießen (File Nr 05/00). Blood DC were enriched in some experiments in a two-step immunomagnetic purification process using the Blood Dendritic Cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer's instructions.

2.2. Multiparameter flow cytometry

Flow Cytometry analyses were performed on a FACS Canto II cytometer equipped with FACS Diva software (Becton Dickinson, San Jose, CA, USA). Monoclonal antibodies were from Biolegend, Germany, unless otherwise indicated. DC-enriched or bulk PBMC sample were incubated for 30 min at 4 °C in PBS pH 7.2 (PAA laboratories, Germany), 2 mM EDTA (Sigma, Germany) and 2% BSA (Serva, Germany) with consensus monoclonal antibodies for mDC1 (CD1c), mDC2 (CD141) and pDC (CD303, Miltenyi Biotec, Germany) [6] and a lineage cocktail (CD14, CD16, CD19, CD20, CD56, TCR $\alpha\beta$) to unambiguously exclude monocytes, B cells, NK cells and T cells. In some experiments with bulk PBMC samples, a reduced lineage cocktail (CD14, CD19) excluding only monocytes and B cells was used. Unspecific Fc-receptor mediated antibody binding was inhibited through pre-incubation with IgG (Gammunex, Talecris, Germany) at a concentration of 0.15% for 15 min at 4 °C. Multiparameter DC subset staining was combined with a panel of PE-labelled mAbs (20 min, 4 °C) targeting 332 surface antigens (<http://www.biolegend.com/legendscreen>) and 10 isotype controls (Legendscreen™ Human Cell Screening, Biolegend, Germany). Fluorescence minus one controls (FMO) were used consistently to control for specificity of surface antigen staining. 25,000–40,000 events were analyzed in surface antigen screening

experiments with DC-enriched samples. 1.5–2 million events were analyzed in confirmatory experiments with bulk PBMC samples. Sytox dye was used according to the manufacturer instructions as a vital dye to exclude non-specific staining of dead cells (Biolegend, Germany).

2.3. Generation of DC

Monocyte-derived DC were generated as described [14,15], with minor modifications. Briefly, CD14⁺ monocytes were purified (>95%) by flow cytometry sorting on a BD FACS Aria III cells sorter (Becton Dickinson, San Jose, CA, USA) using fluorochrome-labelled CD14 monoclonal antibody (Biolegend, Germany) and 1×10^6 cells were cultured for 6–7 days in 1 ml DC medium in 24 well flat bottom plates (Greiner, Frickenhausen, Germany). DC medium contained RPMI 1640 (PAA Laboratories, Linz, Austria), L-Glutamine (PAA Laboratories), penicillin/streptomycin (PAN Biotech, Aidenbach, Germany), sodium-pyruvate (Gibco, Carlsbad, USA), nonessential aminoacids (Sigma), Hepes buffer (Gibco), 10% heat inactivated FCS (PAA Laboratories), 1000 IU/ml recombinant human GM-CSF (Promocell, Heidelberg, Germany) and 1000 IU/ml recombinant human IL-4 (Strathmann, Hamburg, Germany). After 3 days, 50% supernatant was replaced with fresh DC medium. Monocyte-derived DC differentiation (CD1a⁺ CD14^{neg}) was controlled by flow cytometry [15]. In some experiments, DC were stimulated at day 6 with 1 μ g/ml LPS (Sigma, Germany) for 16 h.

3. Results and discussion

3.1. Identification of novel human DC subset marker candidates

In order to acquire a sufficient high number of human DC, including the rare mDC2 subset we first systematically screened DC-enriched PBMC preparations from buffy coats of healthy blood donors. Human DC-enriched PBMC samples were subsequently stained with consensus DC subset surface markers (CD1c, CD141, BDCA-2) and a lineage cocktail to unambiguously




Fig. 1. Identification of human DC subset marker candidates by flow cytometry. DC-enriched blood samples were dissected into mDC1, mDC2 and pDC according to consensus markers CD1c, CD303 (BDCA-2) and CD141 (A–C) and screened for 332 PE-labelled surface markers. Analysis revealed eight DC-subset marker candidates according to signal-to-noise ratio in comparison to isotype-matched FMO controls (D). Previously reported differentially expressed surface markers CD32 (mDC1), CD45RA (pDC), CD64 (mDC1), FcεRI (mDC1), and CD123 (pDC) served as internal controls (E).




Fig. 2. Distinct expression of CD26, CD85a and CD275 on human blood DC subsets PBMC from blood donors were stained with CD26, CD275, CD85a, consensus DC markers CD1c (mDC1), CD141 (mDC2), BDCA-2 (pDC) and lineage markers (CD14, CD16, CD19, CD20, CD56, TCR $\alpha\beta$). (A) Different colors refer to human DC subsets gated in lin^{neg} PBMC according to consensus markers. Figure shows expression of CD26 and CD275 (B) on CD141+ mDC2 and CD85a on CD1c+ mDC1 on lin^{neg} PBMC. (B) Median fluorescence intensity of surface markers and isotype controls in lin^{neg} PBMC from healthy blood donors (mean \pm SEM; $n = 4$).




Fig. 3. Regulation of CD26, CD85a and CD275 expression in monocyte-derived DC CD14+ cells (d0) were differentiated in monocyte-derived DC (d6) in the presence of GM-CSF + IL-4 and stimulated with LPS (d7). CD26, CD85a and CD275 expression was analysed by flow cytometry at different timepoints (d0, d6, d7; mean \pm SEM; $n = 3$).

exclude contaminating non-DC (Fig. 1A). We combined multiparameter DC subset staining method with 332 different PE-labelled surface monoclonal antibodies to identify novel subset markers. Isotype-specific FMO controls were used to precisely evaluate the specificity for surface staining for each DC subset. The initial analysis revealed the presence of eight novel DC subset candidate markers CD26, CD85a, CD109, CD172a, CD200,




Fig. 4. CD275 Expression on CD14 $^{\text{neg}}$ CD19 $^{\text{neg}}$ PBMC Figure shows a staining of CD275 and the mDC2 consensus marker CD141 on CD14 $^{\text{neg}}$ CD19 $^{\text{neg}}$ PBMC. Note that almost all CD141+ PBMC are positive for CD275.

CD200R, CD275 and CD301 (Fig. 1B). Additionally, the analysis included previously reported DC subset markers [7], such as CD123 and CD45RA for pDC and CD32, CD64 and Fc ϵ RI for mDC1 providing an internal control for our experiments.

Table 1

Comparison of mDC2 enumeration in CD14^{neg} CD19^{neg} PBMC with CD275 or CD141 staining.

Donor	CD275 (% of PBMC)	CD141 (% of PBMC)	CD275/CD141 in%
1	0.0128	0.0136	94.1
2	0.0229	0.0224	102.2
3	0.0536	0.0469	114.3
4	0.0477	0.0551	86.5
5	0.0112	0.0100	112.0
Mean	0.0296	0.0296	101.82

3.2. CD26, CD85a and CD275 are novel human blood DC subset markers

The novel DC subset marker candidates were subsequently tested for signal noise ratio with bulk PBMC samples from healthy blood donors (Fig. 2A and B). However, CD109 and CD301 were found to exhibit only low MFI on blood DC in comparison to FMO isotype controls. CD172a, CD200 and CD200R exhibited a partially overlapping expression pattern on blood DC subsets (Fig. 2B). In contrast, CD26, CD85a and CD275 allowed a reliable dissection of blood DC subsets in lineage negative PBMC and correlated most closely with consensus blood DC subset markers (Fig. 2A and B). CD26 and CD275 are expressed at high levels on mDC2 in contrast to mDC1 and pDC. In contrast, CD85a is expressed at high levels on mDC1 in comparison to mDC2 and pDC.

Identification of these three novel human DC subset markers does not only facilitate blood DC subset discrimination but is likely to be of functional relevance because these molecules represent key modulators of T cell activation. CD26 is dipeptidyl peptidase-4 removing X-proline dipeptides from the N-terminus of polypeptides altering the activity of chemokines and cytokines [16,17]. Analysis of recombinant soluble CD26 [18] or Jurkat cells transfected with CD26 [19] revealed that CD26 plays an important role in enhancing T cell proliferation. CD85a or leukocyte immunoglobulin-like receptor B3 (LILRB3) belongs to a group of leukocyte immunoglobulin-like receptors that critically regulate the antigen presenting capacity of DCs [20]. Huang and coworkers recently reported that CD85a and LILRB1 were uniquely up-regulated on myeloid blood DC of HIV-1 elite controllers, i.e. in HIV-1 infected individuals that maintain undetectable viral loads in the absence of antiretroviral therapy [21]. Functional experiments indicated that CD85a and LILRB1 upregulation in HIV elite controllers promoted DC antigen-presenting capacity while inhibiting proinflammatory cytokine production in comparison to HIV-1 progressors and HIV-1 seronegative individuals [21]. Finally, CD275 or inducible costimulatory ligand (ICOS-L) belongs to the B7 protein family and is required for the activation of T effector cells [22].

3.3. CD26, CD85a and CD275 are differentially expressed on monocyte-derived DC

Because GM-CSF/IL-4 monocyte-derived DC (moDC) are commonly used as a model system to study myeloid DC differentiation we have analyzed the expression pattern of CD26, CD85a and CD275 in blood monocytes differentiating into myeloid DC (Fig. 3). The blood mDC1 marker CD85a and the mDC2 marker CD275 were markedly up-regulated on moDC. In contrast, expression of the mDC2 marker CD26 was not induced on moDC. The high expression of CD85a on moDC is intriguing because simian immunodeficiency virus (SIV) and HIV-loaded moDC have been used successfully as therapeutic DC vaccine in SIV-infected rhesus monkeys and HIV-infected human patients [23,24] and high CD85a expression on myeloid blood DCs has been strongly correlated with elite

HIV-1 controllers [21]. Further studies are clearly warranted to dissect the functional role of CD85a expression on myeloid DC and HIV pathogenesis.

3.4. CD275 improves identification of rare CD141+ (BDCA-3) mDC2 in human peripheral blood

Since CD141+ DC represent the smallest human blood DC subset and only a few mDC2 selective markers have been reported we questioned whether CD275 can improve the standard identification of mDC2 in human blood. Our analysis of PBMC samples indicated that CD275 expression correlated almost completely with CD141 (BDCA-3) expression in CD14/CD19 negative PBMC suggesting that CD275 was useful for identification of mDC2 in human blood (Fig. 4). Moreover, enumeration of mDC2 via CD275 staining yielded almost identical quantitative results when compared to the standard CD141 staining (Table 1). However, since the expression of both CD275 and CD141 can change during culture or stimulation we found the combination of CD141 and CD275 most useful for the unambiguous identification of human blood mDC2 (Fig. 4).

In summary, we have identified three novel human blood DC subset markers that can facilitate precise human blood DC identification and enumeration. Moreover, the identification of CD26 and CD275 as mDC2 markers and CD85a as mDC1 marker have revealed novel targets promoting our understanding of the functional heterogeneity of human blood DC subsets.

Acknowledgments

We thank Ms. Gabriela Michel for excellent technical support. The work was supported by the Excellence Cluster Cardio-Pulmonary System, German Science Foundation (HH; ECCPS) and the CRC Transregio 84, German Science Foundation, Innate Immunity of the Lung: Mechanisms of Pathogen Attack and Host Defence in Pneumonia (Project B3 HH).

References

- [1] H. Hackstein, A. Thomson, Dendritic cells: emerging pharmacological targets of immunosuppressive drugs, *Nat. Rev. Immunol.* 4 (2004) 24–34.
- [2] J. Banachereau, E. Klechevsky, N. Schmitt, R. Morita, K. Palucka, H. Ueno, Harnessing human dendritic cell subsets to design novel vaccines, *Ann. N. Y. Acad. Sci.* 1174 (2009) 24–32.
- [3] R. Steinman, J. Banachereau, Taking dendritic cells into medicine, *Nature* 449 (2007) 419–426.
- [4] M. Merad, P. Sathe, J. Helft, J. Miller, A. Mortha, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, *Annu. Rev. Immunol.* 31 (2013) 563–604.
- [5] H. Hackstein, F.C. Renner, A. Bohnert, A. Nockher, T. Frommer, G. Bein, R. Weimer, Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: results of a prospective matched-cohort study, *Am. J. Transplant.* 5 (2005) 2945–2953.
- [6] L. Ziegler-Heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau, D.N. Hart, P.J.M. Leenen, Y.-J. Liu, G. MacPherson, G.J. Randolph, J. Scherberich, J. Schmitz, K. Shortman, S. Sozzani, H. Strobl, M. Zembala, J.M. Austyn, M.B. Lutz, Nomenclature of monocytes and dendritic cells in blood, *Blood* 116 (2010) e74–80.
- [7] A. Dzionek, A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D.W. Buck, J. Schmitz, BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood, *J. Immunol.* 165 (2000) 6037–6046.
- [8] A.J. Kassianos, M.Y. Hardy, X. Ju, D. Vijayan, Y. Ding, A.J.E. Vulink, K.J. McDonald, S.L. Jongbloed, R.B. Wadley, C. Wells, D.N.J. Hart, K.J. Radford, Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immunoregulatory phenotype and function in response to *Escherichia coli*, *Eur. J. Immunol.* 42 (2012) 1512–1522.
- [9] S. Meixlsperger, C.S. Leung, P.C. Ramer, M. Pack, L.D. Vanoaica, G. Breton, S. Pascolo, A.M. Salazar, A. Dzionek, J. Schmitz, R.M. Steinman, C. Munz, CD141+ dendritic cells produce prominent amounts of IFN- α after dsRNA recognition and can be targeted via DEC-205 in humanized mice, *Blood* 121 (2013) 5034–5044.
- [10] G. Schreibeit, L.J.J. Klinkenberg, L.J. Cruz, P.J. Tacken, J. Tel, M. Kreutz, G.J. Adema, G.D. Brown, C.G. Figdor, I.J.M. de Vries, The C-type lectin receptor

- CLEC9A mediates antigen uptake and (cross-) presentation by human blood BDCA3+ myeloid dendritic cells, *Blood* 119 (2012) 2284–2292.
- [11] T.W.H. Flinsenberg, E.B. Compeer, D. Koning, M. Klein, F.J. Amelung, D. van Baarle, J.J. Boelens, M. Boes, Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells, *Blood* 120 (2012) 5163–5172.
- [12] S.L. Jongbloed, A.J. Kassianos, K.J. McDonald, G.J. Clark, X. Ju, C.E. Angel, C.-J.J. Chen, P.R. Dunbar, R.B. Wadley, V. Jeet, A.J.E. Vulink, D.N.J. Hart, K.J. Radford, Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens, *J. Exp. Med.* 207 (2010) 1247–1260.
- [13] P. Autissier, C. Soulas, T.H. Burdo, K.C. Williams, Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans, *Cytometry A* 77 (2010) 410–419.
- [14] C. Steinschulte, T. Taner, A.W. Thomson, G. Bein, H. Hackstein, Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells, *J. Immunol.* 171 (2003) 542–546.
- [15] H. Hackstein, A. Knoche, A. Nockher, J. Poeling, T. Kubin, M. Jurk, J. Vollmer, G. Bein, The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation, *Cell. Immunol.* 271 (2011) 401–412.
- [16] K. Ohnuma, N.H. Dang, C. Morimoto, Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function, *Trends. Immunol.* 29 (2008) 295–301.
- [17] E. Matteucci, O. Giampietro, Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme, *Curr. Med. Chem.* 16 (2009) 2943–2951.
- [18] T. Tanaka, J.S. Duke-Cohan, J. Kameoka, A. Yaron, I. Lee, S.F. Schlossman, C. Morimoto, Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV, *Proc. Natl. Acad. Sci. USA* 91 (1994) 3082–3086.
- [19] T. Tanaka, J. Kameoka, A. Yaron, S.F. Schlossman, C. Morimoto, The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity, *Proc. Natl. Acad. Sci. USA* 90 (1993) 4586–4590.
- [20] M. Lichterfeld, X.G. Yu, The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection, *J. Leukoc. Biol.* 91 (2012) 27–33.
- [21] J. Huang, P.S. Burke, T.D.H. Cung, F. Pereyra, I. Toth, B.D. Walker, L. Borges, M. Lichterfeld, X.G. Yu, Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers, *J. Virol.* 84 (2010) 9463–9471.
- [22] K.M. Hamel, Y. Cao, S.A. Olalekan, A. Finnegan, B cell specific expression of ICOSL is necessary for the induction of arthritis, *Arthritis Rheum.* (2013).
- [23] W. Lu, X. Wu, Y. Lu, W. Guo, J.-M. Andrieu, Therapeutic dendritic-cell vaccine for simian AIDS, *Nat. Med.* 9 (2003) 27–32.
- [24] W. Lu, L.C. Arraes, W.T. Ferreira, J.-M. Andrieu, Therapeutic dendritic-cell vaccine for chronic HIV-1 infection, *Nat. Med.* 10 (2004) 1359–1365.